igxt
- Creatore Discussione axelvento
- Data di inizio
IntelGenx Reports Record Third Quarter 2015 Financial Results
IntelGenx annuncia risultati record del terzo trimestre 2015 risultati finanziari. Possibilità di uscire dal mercato OTC?
IntelGenx annuncia risultati record del terzo trimestre 2015 risultati finanziari. Possibilità di uscire dal mercato OTC?
playars
lotto players
- Registrato
- 11/4/08
- Messaggi
- 8.306
- Punti reazioni
- 174
axelvento
dCellVax
- Registrato
- 21/12/04
- Messaggi
- 16.246
- Punti reazioni
- 419
newsssssss
RedHill Biopharma and IntelGenx Announce First European Marketing Approval of RIZAPORT(TM) (RHB-103) for Migraines
RedHill Biopharma and IntelGenx Announce First European Marketing Approval of RIZAPORT(TM) (RHB-103) for Migraines - OTCMarkets.com
RedHill Biopharma and IntelGenx Announce First European Marketing Approval of RIZAPORT(TM) (RHB-103) for Migraines
RedHill Biopharma and IntelGenx Announce First European Marketing Approval of RIZAPORT(TM) (RHB-103) for Migraines - OTCMarkets.com
axelvento
dCellVax
- Registrato
- 21/12/04
- Messaggi
- 16.246
- Punti reazioni
- 419
gold money
Member
- Registrato
- 22/3/09
- Messaggi
- 2.231
- Punti reazioni
- 533
Entrato adesso a 0.50 long
IGXT just added $1M a year in salaries.
.
IGXT just added 4 employees to the management and advisory teams. These 4 new salaries should add, by my estimates, nearly $1M dollars a year in salaries. An analyst estimate has IGXT bringing-in $11.3M in revenues this year, so adding $1M more a year to operating costs will be absorbed by this rise in revenues.
It's interesting to see the backgrounds of the new employees added. There is a lot of clues that show IGXT is on the verge of doing great things.
IGXT has created a Scientific Advisory Board and added 2 neuroscientists, Dr. Ludwig Aigner, who has done extensive research in regenerative medicine and Dr. Barry Greenberg, who has extensive experience in Alzheimer's research.
Mark Nawacki will serve as an advisor, he specializes in Acquisition and Commercialization on innovative and unique healthcare products. I doubt IGXT is looking to build-up a 20-man sales force and acquire more products to market along it's own. However, that would be a great move for IGXT to have their own marketing team. I think Nawacki's role will be to find marketing partners for current and future products.
IGXT also added Robert Bechard and Edward Miller to their team. These 2 specialize in the investing and stock market part of the company.
.
IGXT just added 4 employees to the management and advisory teams. These 4 new salaries should add, by my estimates, nearly $1M dollars a year in salaries. An analyst estimate has IGXT bringing-in $11.3M in revenues this year, so adding $1M more a year to operating costs will be absorbed by this rise in revenues.
It's interesting to see the backgrounds of the new employees added. There is a lot of clues that show IGXT is on the verge of doing great things.
IGXT has created a Scientific Advisory Board and added 2 neuroscientists, Dr. Ludwig Aigner, who has done extensive research in regenerative medicine and Dr. Barry Greenberg, who has extensive experience in Alzheimer's research.
Mark Nawacki will serve as an advisor, he specializes in Acquisition and Commercialization on innovative and unique healthcare products. I doubt IGXT is looking to build-up a 20-man sales force and acquire more products to market along it's own. However, that would be a great move for IGXT to have their own marketing team. I think Nawacki's role will be to find marketing partners for current and future products.
IGXT also added Robert Bechard and Edward Miller to their team. These 2 specialize in the investing and stock market part of the company.
playars
lotto players
- Registrato
- 11/4/08
- Messaggi
- 8.306
- Punti reazioni
- 174
se uno legge tutte le news
si domanda ma com'è possibile
che nn si muove...???
tempo al tempo..
la pazienza è la virtu' che manca
a tante persone!!!!!
IntelGenX Corp. - Home
playars
lotto players
- Registrato
- 11/4/08
- Messaggi
- 8.306
- Punti reazioni
- 174
axelvento
dCellVax
- Registrato
- 21/12/04
- Messaggi
- 16.246
- Punti reazioni
- 419
Ottimi risultati azienda in crescita, -20% crollo dell'azione da 0,60$ a 0,48$
Non si riesce a decollare, qualcuno mi sa dire come mai???
axelvento
dCellVax
- Registrato
- 21/12/04
- Messaggi
- 16.246
- Punti reazioni
- 419
Ottimi risultati azienda in crescita, -20% crollo dell'azione da 0,60$ a 0,48$
Non si riesce a decollare, qualcuno mi sa dire come mai???
buongiorno,,,,,
tutto bene?
dimenticala per tutto il 2016
vedrai che poi il portafoglio lo troverai gonfio sperem!!!!!!
ottima azienda igxt
è solo questione di tempo
IntelGenx Corp., (TSX VENTURE:IGX)(IGXT), today announced the signing of a term sheet with a global pharmaceutical company for the development and commercialization of up to three products utilizing IntelGenx' proprietary VersaFilm™ technology. Pursuant to the term sheet, IntelGenx granted an exclusive negotiation period during which time the parties will conduct diligence and work towards entry into a definitive agreement. IntelGenx receives $100,000 at the time of signing the term sheet, in consideration for granting an exclusive negotiation right. If entered into, IntelGenx expects the definitive agreement to be finalized by the second quarter of 2016.
According to the term sheet, IntelGenx will grant exclusive rights to market and sell up to three products in the United States. The term sheet contemplates that IntelGenx will receive, in consideration for such exclusive rights, upfront and milestone payments, together with a share of profits, and also contemplates transfer of development costs to the counter-party. Entry into a definitive agreement remains subject to satisfaction of diligence by each party.
axelvento
dCellVax
- Registrato
- 21/12/04
- Messaggi
- 16.246
- Punti reazioni
- 419
axelvento
dCellVax
- Registrato
- 21/12/04
- Messaggi
- 16.246
- Punti reazioni
- 419
axelvento
dCellVax
- Registrato
- 21/12/04
- Messaggi
- 16.246
- Punti reazioni
- 419
$.90 la paura
IntelGenx to Present at the 18th Annual Rodman & Renshaw Global Investment Conference and the 11th Annual Singular Research ConferenceFont
9:53 AM ET 9/7/16 | Marketwired
SAINT-LAURENT, CANADA--(Marketwired - Sep 7, 2016) - IntelGenx Corp., (TSX VENTURE:IGX) (OTCQX:IGXT), today announced that Dr. Horst Zerbe, President and Chief Executive Officer, will present at two upcoming conferences. Also present and available for questions will be Andre Godin, Executive Vice-President and Chief Financial Officer.
Rodman & Renshaw 18th Annual Global Investment Conference
Date: Monday, September 12
Location: Lotte New York Palace Hotel, New York City
Presentation Time: 10:50 AM Eastern Time
11th Annual Singular Research Conference "Best of the Uncovereds"
Date: Thursday, September 22
Location: Luxe Sunset Boulevard Hotel, Los Angeles
About IntelGenx:
IntelGenx is a leading oral drug delivery company focused on the development and manufacturing of innovative pharmaceutical oral films based on its proprietary VersaFilm™ technology platform. Established in 2003, the Montreal-based company is listed on the TSX-V and OTC-QX.
IntelGenx highly skilled team provides comprehensive pharmaceuticals services to pharmaceutical partners, including R&D, analytical method development, clinical monitoring, IP and regulatory services. IntelGenx state-of-the art manufacturing facility, established for the VersaFilm™ technology platform, supports lab-scale to pilot and commercial-scale production, offering full service capabilities to our clients. More information is available about the company at: www.intelgenx.com.
Forward Looking Statements:
This document may contain forward-looking information about IntelGenx' operating results and business prospects that involve substantial risks and uncertainties. Statements that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, but are not limited to, statements about IntelGenx' plans, objectives, expectations, strategies, intentions or other characterizations of future events or circumstances and are generally identified by the words "may," "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates," "could," "would," and similar expressions. All forward looking statements are expressly qualified in their entirety by this cautionary statement. Because these forward-looking statements are subject to a number of risks and uncertainties, IntelGenx' actual results could differ materially from those expressed or implied by these forward looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed under the heading "Risk Factors" in IntelGenx' annual report on Form 10-K, filed with the United States Securities and Exchange Commission and available at www.sec.gov, and also filed with Canadian securities regulatory authorities and www.sedar.com. IntelGenx assumes no obligation to update any such forward-looking statements.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange), nor the OTCQX accepts responsibility for the adequacy or accuracy of this release.
Source: IntelGenx Technologies Corp.
Edward Miller Director, IR and Corporate Communications IntelGenx Corp. +1 514-331-7440 (ext. 217) edward@intelgenx.com
IntelGenx to Present at the 18th Annual Rodman & Renshaw Global Investment Conference and the 11th Annual Singular Research ConferenceFont
9:53 AM ET 9/7/16 | Marketwired
SAINT-LAURENT, CANADA--(Marketwired - Sep 7, 2016) - IntelGenx Corp., (TSX VENTURE:IGX) (OTCQX:IGXT), today announced that Dr. Horst Zerbe, President and Chief Executive Officer, will present at two upcoming conferences. Also present and available for questions will be Andre Godin, Executive Vice-President and Chief Financial Officer.
Rodman & Renshaw 18th Annual Global Investment Conference
Date: Monday, September 12
Location: Lotte New York Palace Hotel, New York City
Presentation Time: 10:50 AM Eastern Time
11th Annual Singular Research Conference "Best of the Uncovereds"
Date: Thursday, September 22
Location: Luxe Sunset Boulevard Hotel, Los Angeles
About IntelGenx:
IntelGenx is a leading oral drug delivery company focused on the development and manufacturing of innovative pharmaceutical oral films based on its proprietary VersaFilm™ technology platform. Established in 2003, the Montreal-based company is listed on the TSX-V and OTC-QX.
IntelGenx highly skilled team provides comprehensive pharmaceuticals services to pharmaceutical partners, including R&D, analytical method development, clinical monitoring, IP and regulatory services. IntelGenx state-of-the art manufacturing facility, established for the VersaFilm™ technology platform, supports lab-scale to pilot and commercial-scale production, offering full service capabilities to our clients. More information is available about the company at: www.intelgenx.com.
Forward Looking Statements:
This document may contain forward-looking information about IntelGenx' operating results and business prospects that involve substantial risks and uncertainties. Statements that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, but are not limited to, statements about IntelGenx' plans, objectives, expectations, strategies, intentions or other characterizations of future events or circumstances and are generally identified by the words "may," "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates," "could," "would," and similar expressions. All forward looking statements are expressly qualified in their entirety by this cautionary statement. Because these forward-looking statements are subject to a number of risks and uncertainties, IntelGenx' actual results could differ materially from those expressed or implied by these forward looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed under the heading "Risk Factors" in IntelGenx' annual report on Form 10-K, filed with the United States Securities and Exchange Commission and available at www.sec.gov, and also filed with Canadian securities regulatory authorities and www.sedar.com. IntelGenx assumes no obligation to update any such forward-looking statements.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange), nor the OTCQX accepts responsibility for the adequacy or accuracy of this release.
Source: IntelGenx Technologies Corp.
Edward Miller Director, IR and Corporate Communications IntelGenx Corp. +1 514-331-7440 (ext. 217) edward@intelgenx.com